Image source: Shutterstock

Highlights

  • In H1 FY23, Uniphar hit a landmark achievement of doubling its 2018 pro forma EBITDA before the timeframe set at the time of IPO.
  • Uniphar’s revenue has increased by approximately 25.0% in the reporting period.
  • There has been a 9% year-on-year growth in the company’s interim dividend payment for H1 FY23.

FTSE AIM 100 index listed Uniphar PLC (LSE: UPR) is a diversified healthcare services business serving over 200 multinational pharmaceutical and medical technology companies. The company is aiming expansion in continental Europe and the Asia-Pacific (APAC) region with new acquisitions of BModesto and Orspec in its Product Access division.

In the first half of the fiscal year 2023, the company hit a landmark achievement of doubling its 2018 pro forma EBITDA before the timeframe set at the time of IPO. For H1 FY23, there has been a 4.9% year-on-year growth in the company’s interim dividend payment.

Uniphar’s revenue has increased by approximately 25.0% in the reporting period. Its operating profit witnessed a 11.7% year-on-year growth to €28.01 million in the first half of the fiscal year 2023.

The company paid an interim dividend of 0.64 euro cents per share last month, with an ex-dividend date of 28 September 2023.

The company is targeting better market leadership position in Supply Chain & Retail division with strategic investment and acquisitions. UPR will be making a huge investment of approximately €60 million of strategic capital expenditure in an IT and ERP investment programme in the coming future. It has set an ambitious new target of elevating the group EBITDA to €200 million over the medium-term.

Top 10 Shareholders:

Around 43.92% of the total shareholdings is held by its top ten shareholders. While Allianz Global Investors GmbH owns the maximum number of shares with approximately 11.02% shareholding, Polar Capital LLP holds over 7 % shareholding in the firm. 

 

 

Stock Price Performance and Technical Summary:

UPR’s stock price dropped by approximately 2.67% in the last one month. It has fallen by more than 34.35% over the last six months. The stock’s 52-week low and high price stand at GBX 178.00 and GBX 334.00, respectively.

 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 29 November 2023. The reference data in this report has been partly sourced from EODHD/Others.